FDA grants Priority Review to Genentech's Enspryng for MOGAD

BioMarin announces positive Phase 3 VOXZOGO (vosoritide) study results in hypochondroplasia published in NEJM Evidence

Seismic Pharmaceuticals enrols first patient in istaroxime global Phase 3 trial in cardiogenic shock

BioEdge Research Labs advances transparency in research compound documentation

Insilico Medicine doses first patient in Phase III trial of rentosertib

BridgeBio reports exploratory PROPEL 3 data showing wider clinical trends for oral infigratinib

Tyra Biosciences declares positive Phase 2 results for oral dabogratinib in bladder cancer

Harbour BioMed partner raises USD225m to advance neoadjuvant immuno-oncology therapy porustobart

Kazia Therapeutics doses first patient in paediatric AT/RT study

Fusion Antibodies secures Canadian patent for OptiMAL

Revvity to acquire Human Cell Design to expand metabolic disease drug discovery capabilities

Biophytis expands BIO101 obesity study to assess weight regain

THX Pharma secures European patent for Batten-1 in juvenile Batten disease

Orphalan commences Phase 3 study of trientine therapy in Wilson disease

ZAGENO named Frost & Sullivan's 2026 North American Life Sciences E-Commerce Company of the Year